Skip to main content

OMEGA HEALTHCARE INVESTORS INC

For the period ended Jun 30, 2025. Filed Aug 1, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 1, 2025

OHI$48.70-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Cash Flows

Unaudited (in thousands)

​​​​​​​
​Six Months Ended June 30,
​ · 2025 · 2024
Cash flows from operating activities · ​ · ​
Net income​$252,539​$186,425
Adjustment to reconcile net income to net cash provided by operating activities:​​​
Depreciation and amortization​160,384​148,791
Impairment on real estate properties​15,450​13,474
Straight-line rent and other write-offs​​27,537​​—
Provision (recovery) for credit losses​321​(5,702)
Amortization of deferred financing costs and loss on debt extinguishment​2,396​8,534
Stock-based compensation expense​25,046​18,415
Gain on assets sold – net​(32,961)​(11,520)
Straight-line rent and effective interest receivables​(23,526)​(17,857)
Interest paid-in-kind​​(4,996)​​(6,674)
Loss from unconsolidated joint ventures​​3,066​​1,617
Other non-cash items​(4,358)​(992)
Change in operating assets and liabilities – net:​​​
Contractual receivables​1,059​1,406
Lease inducements​(9,497)​465
Other operating assets and liabilities​8,757​(805)
Net cash provided by operating activities​421,217​335,577
Cash flows from investing activities​​​​
Acquisition of real estate​(560,422)​(127,973)
Net proceeds from sale of real estate investments​182,995​44,894
Investments in construction in progress​(29,731)​(42,149)
Investment in loan receivables and other​(109,767)​(193,187)
Collection of loan principal​100,297​65,435
Investments in unconsolidated joint ventures​​(1,250)​​(318)
Distributions from unconsolidated joint ventures in excess of earnings​1,466​1,250
Capital improvements to real estate investments​(32,941)​(14,010)
Proceeds from derivative instruments​4,675​8,429
Receipts from insurance proceeds​392​1,657
Net cash used in investing activities​(444,286)​(255,972)
Cash flows from financing activities​​
Proceeds from long-term borrowings​670,708​478,500
Payments of long-term borrowings​(527,240)​(890,128)
Payments of financing related costs​(6,540)​(1,892)
Net proceeds from issuance of common stock​517,851​275,186
Dividends paid​(383,785)​(330,720)
Net payments to noncontrolling members of consolidated joint venture​—​545
Redemption of Omega OP Units​​(3,681)​​—
Distributions to Omega OP Unit Holders​(26,056)​(16,712)
Net cash provided by (used in) financing activities​241,257​(485,221)
Effect of foreign currency translation on cash, cash equivalents and restricted cash​5,661​17
Increase (decrease) in cash, cash equivalents and restricted cash​223,849​(405,599)
Cash, cash equivalents and restricted cash at beginning of period​548,735​444,730
Cash, cash equivalents and restricted cash at end of period​$772,584​$39,131
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.